KR102530129B1 - 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도 - Google Patents

중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도 Download PDF

Info

Publication number
KR102530129B1
KR102530129B1 KR1020167034871A KR20167034871A KR102530129B1 KR 102530129 B1 KR102530129 B1 KR 102530129B1 KR 1020167034871 A KR1020167034871 A KR 1020167034871A KR 20167034871 A KR20167034871 A KR 20167034871A KR 102530129 B1 KR102530129 B1 KR 102530129B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167034871A
Other languages
English (en)
Korean (ko)
Other versions
KR20170002639A (ko
Inventor
잰 매릭
조셉 피 라이시카토스
시몬 윌리암스
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Priority to KR1020237006997A priority Critical patent/KR102618139B1/ko
Publication of KR20170002639A publication Critical patent/KR20170002639A/ko
Application granted granted Critical
Publication of KR102530129B1 publication Critical patent/KR102530129B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020167034871A 2014-05-13 2015-05-12 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도 Active KR102530129B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237006997A KR102618139B1 (ko) 2014-05-13 2015-05-12 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
US61/992,717 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006997A Division KR102618139B1 (ko) 2014-05-13 2015-05-12 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도

Publications (2)

Publication Number Publication Date
KR20170002639A KR20170002639A (ko) 2017-01-06
KR102530129B1 true KR102530129B1 (ko) 2023-05-10

Family

ID=53269446

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167034871A Active KR102530129B1 (ko) 2014-05-13 2015-05-12 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도
KR1020237006997A Active KR102618139B1 (ko) 2014-05-13 2015-05-12 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237006997A Active KR102618139B1 (ko) 2014-05-13 2015-05-12 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3143011B1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102530129B1 (enExample)
CN (2) CN110483522B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX376163B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG11201609281UA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280791B2 (en) 2014-05-13 2024-03-01 Hoffmann La Roche Deuterated compounds and uses thereof
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
SG11201811311VA (en) 2016-07-22 2019-01-30 Ac Immune Sa Compounds for imaging tau protein aggregates
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CA3113234A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
ES2945834T3 (es) 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
TWI804079B (zh) * 2019-05-09 2023-06-01 瑞士商赫孚孟拉羅股份公司 經標記之咪唑并[1,2-a]嘧啶之合成
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143432A1 (en) 2007-09-13 2009-06-04 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US20110182812A1 (en) 2009-03-23 2011-07-28 Siemens Medical Solutions Usa, Inc. Imaging Agents for Detecting Neurological Disorders
JP2014502257A (ja) 2010-10-22 2014-01-30 ピラマル イメージング ソシエテ アノニム 中枢神経系の疾患を画像化、診断及び／又は治療するために使用する化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD76515A (enExample) *
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
SG173338A1 (en) 2006-03-30 2011-08-29 Univ Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
JP2011512354A (ja) 2008-02-14 2011-04-21 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経機能障害を検知するための新規の造影剤
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
WO2010111303A2 (en) 2009-03-23 2010-09-30 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
BR112013011737A2 (pt) * 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
AU2012381042B2 (en) * 2012-05-22 2015-10-01 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
PT3055308T (pt) * 2013-10-08 2018-01-18 Hoffmann La Roche Resumo
IL280791B2 (en) 2014-05-13 2024-03-01 Hoffmann La Roche Deuterated compounds and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143432A1 (en) 2007-09-13 2009-06-04 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US20110182812A1 (en) 2009-03-23 2011-07-28 Siemens Medical Solutions Usa, Inc. Imaging Agents for Detecting Neurological Disorders
JP2013522365A (ja) 2010-03-23 2013-06-13 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経性疾患の検出のためのイメージング剤
JP2014502257A (ja) 2010-10-22 2014-01-30 ピラマル イメージング ソシエテ アノニム 中枢神経系の疾患を画像化、診断及び／又は治療するために使用する化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Amarnath Challapalli et al. The Journal of Nuclear Medicien. 2014, Vol. 55, pp. 256-263*
Mingzhang Gao et al. Bioorganic and Medicinal Chemistry Letters. 2014, Vol. 24. pp. 254-257*

Also Published As

Publication number Publication date
CA2948721A1 (en) 2015-11-19
BR112016026443A2 (pt) 2017-08-15
AU2015261008A1 (en) 2016-11-17
MX376163B (es) 2025-03-07
RU2016147742A3 (enExample) 2018-10-08
WO2015173225A1 (en) 2015-11-19
US20200297875A1 (en) 2020-09-24
IL280791B1 (en) 2023-11-01
RU2016147742A (ru) 2018-06-18
LT3143011T (lt) 2021-05-10
CN106459059A (zh) 2017-02-22
JP2019147825A (ja) 2019-09-05
AU2019203369A1 (en) 2019-06-06
EP3143011B1 (en) 2021-03-03
IL280791A (en) 2021-04-29
CN110483522B (zh) 2022-05-03
IL271631A (en) 2020-02-27
US12214058B2 (en) 2025-02-04
MX2016014615A (es) 2017-03-06
CN110483522A (zh) 2019-11-22
US20190201561A1 (en) 2019-07-04
AU2015261008B2 (en) 2019-02-14
NZ764181A (en) 2023-11-24
MX2020010847A (es) 2021-07-16
KR102618139B1 (ko) 2023-12-27
SI3143011T1 (sl) 2021-08-31
KR20170002639A (ko) 2017-01-06
JP6529986B2 (ja) 2019-06-12
JP6681498B2 (ja) 2020-04-15
EP3901145A1 (en) 2021-10-27
US20160250358A1 (en) 2016-09-01
CA2948721C (en) 2023-03-28
ES2867814T3 (es) 2021-10-20
CN106459059B (zh) 2019-09-24
IL248692B (en) 2020-01-30
BR112016026443A8 (pt) 2021-07-06
US20230218782A1 (en) 2023-07-13
US10076581B2 (en) 2018-09-18
PT3143011T (pt) 2021-04-26
US10675367B2 (en) 2020-06-09
HRP20210641T1 (hr) 2021-05-28
AU2019203369B2 (en) 2020-06-04
MX384604B (es) 2025-03-14
SG11201609281UA (en) 2016-12-29
US11504440B2 (en) 2022-11-22
IL248692A0 (en) 2017-01-31
JP2017515856A (ja) 2017-06-15
EP3143011A1 (en) 2017-03-22
IL271631B (en) 2021-05-31
DK3143011T3 (da) 2021-05-03
KR20230035445A (ko) 2023-03-13
PL3143011T3 (pl) 2021-07-19
NZ726208A (en) 2023-11-24
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
HUE053939T2 (hu) 2021-08-30
RS61810B1 (sr) 2021-06-30
IL280791B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
KR102530129B1 (ko) 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도
BRPI0806621A2 (pt) composto, uso de um composto, composição farmacêutica, e, método in vivo para medir depósitos amilóides em um indivìduo
WO2019121661A1 (en) Radiolabeled compounds
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
CN109475594A (zh) 用于成像ido1酶的放射性配体
RU2791900C1 (ru) Дейтрированные гетероциклические соединения и их применение в качестве средств визуализации
HK40014375B (zh) 氘化杂环化合物和其作为成像剂的用途
HK40014375A (en) Deuterated heterocyclic compounds and their use as imaging agents
HK1228902B (zh) 氘化杂环化合物和其作为成像剂的用途
BR112016026443B1 (pt) Compostos heterocíclicos deuterados, seus usos, e composição farmacêutica
HK1228902A1 (en) Deuterated heterocyclic compounds and their use as imaging agents
US20220280661A1 (en) Glucocorticoid receptor radioligands and methods for their preparation and use
TW201929909A (zh) 放射性核種標識化合物及含有其之成像劑
CA3031079C (en) Radioligands for imaging the ido1 enzyme

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000